Vault-13

5AM Venture Management, LLC

SAN FRANCISCO, CA · CIK 1799883 · 13F filing filed 2025-08-14

SEC-registered investment adviser since 2021 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
San Francisco, CA (main office)United States United Statesabout 8
Boston, MAUnited States United States7
New York, NYUnited States United States3

US visa salary filings

Job titleFilingsMedianRange
Senior Research AnalystNew York, NY 1 $350,000

Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: 5AM Venture Management, LLC.

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$260.1m reported value -1.6% vs Q1 2025
29positions
66.6%in top 10
0 new 0 added 3 reduced 2 sold out vs Q1 2025

Holdings, Q2 2025

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 SKYE BIOSCIENCE INC COM NEW COM NEW 9,913,168 $41.4m15.93% 15.93% UnchangedShares held: Q3 2024 9.9m, Q4 2024 9.9m, Q1 2025 9.9m, Q2 2025 9.9m
2 ENTRADA THERAPEUTICS INC COM TRDA TRDA 4,308,379 $29.0m11.13% 11.13% ReducedShares held: Q3 2024 4.4m, Q4 2024 4.4m, Q1 2025 4.4m, Q2 2025 4.3m -100.0k -100,000 -2.3%
3 DIANTHUS THERAPEUTICS INC COM DNTH DNTH 984,725 $18.3m7.05% 7.05% ReducedShares held: Q3 2024 1.2m, Q4 2024 1.0m, Q1 2025 1.0m, Q2 2025 984.7k -43.0k -42,986 -4.2%
4 ENLIVEN THERAPEUTICS INC COM ELVN ELVN 772,477 $15.5m5.96% 5.96% ReducedShares held: Q3 2024 1.8m, Q4 2024 1.6m, Q1 2025 1.3m, Q2 2025 772.5k -550.0k -550,000 -41.6%
5 PHARVARIS N V COM PHVS PHVS 797,600 $14.0m5.40% 5.40% UnchangedShares held: Q3 2024 797.6k, Q4 2024 797.6k, Q1 2025 797.6k, Q2 2025 797.6k
6 MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD MLTX MLTX 282,313 $13.3m5.12% 5.12% UnchangedShares held: Q3 2024 282.3k, Q4 2024 282.3k, Q1 2025 282.3k, Q2 2025 282.3k
7 CENTESSA PHARMACEUTICALS PLC SPONSORED ADS SPONSORED ADS 830,945 $10.9m4.20% 4.20% UnchangedShares held: Q3 2024 1.3m, Q4 2024 830.9k, Q1 2025 830.9k, Q2 2025 830.9k
8 VOR BIOPHARMA INC COM COM 6,361,723 $10.3m3.96% 3.96% UnchangedShares held: Q3 2024 6.4m, Q4 2024 6.4m, Q1 2025 6.4m, Q2 2025 6.4m
9 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 736,595 $10.3m3.96% 3.96% UnchangedShares held: Q3 2024 736.6k, Q4 2024 736.6k, Q1 2025 736.6k, Q2 2025 736.6k
10 TECTONIC THERAPEUTIC INC COM TECX TECX 511,660 $10.2m3.91% 3.91% UnchangedShares held: Q3 2024 646.5k, Q4 2024 596.7k, Q1 2025 511.7k, Q2 2025 511.7k
11 CELLDEX THERAPEUTICS INC NEW COM NEW CLDX CLDX 497,270 $10.1m3.89% 3.89% UnchangedShares held: Q3 2024 497.3k, Q4 2024 497.3k, Q1 2025 497.3k, Q2 2025 497.3k
12 EYEPOINT PHARMACEUTICALS INC COM NEW EYPT EYPT 1,050,000 $9.9m3.80% 3.80% UnchangedShares held: Q3 2024 1.1m, Q4 2024 1.1m, Q1 2025 1.1m, Q2 2025 1.1m
13 TYRA BIOSCIENCES INC COM TYRA TYRA 939,298 $9.0m3.46% 3.46% UnchangedShares held: Q3 2024 939.3k, Q4 2024 939.3k, Q1 2025 939.3k, Q2 2025 939.3k
14 PRAXIS PRECISION MEDICINES I COM NEW PRAX PRAX 170,000 $7.1m2.75% 2.75% UnchangedShares held: Q3 2024 340.0k, Q4 2024 170.0k, Q1 2025 170.0k, Q2 2025 170.0k
15 GH RESEARCH PLC ORDINARY SHARES GHRS GHRS 572,665 $7.0m2.68% 2.68% UnchangedShares held: Q3 2024 572.7k, Q4 2024 572.7k, Q1 2025 572.7k, Q2 2025 572.7k
16 ERASCA INC COM ERAS ERAS 5,405,404 $6.9m2.64% 2.64% UnchangedShares held: Q3 2024 5.4m, Q4 2024 5.4m, Q1 2025 5.4m, Q2 2025 5.4m
17 BIOHAVEN LTD COM BHVN BHVN 478,972 $6.8m2.60% 2.60% UnchangedShares held: Q3 2024 479.0k, Q4 2024 479.0k, Q1 2025 479.0k, Q2 2025 479.0k
18 VIKING THERAPEUTICS INC COM VKTX VKTX 189,593 $5.0m1.93% 1.93% UnchangedShares held: Q3 2024 237.6k, Q4 2024 189.6k, Q1 2025 189.6k, Q2 2025 189.6k
19 SCPHARMACEUTICALS INC COM SCPH SCPH 1,200,647 $4.6m1.76% 1.76% UnchangedShares held: Q3 2024 1.2m, Q4 2024 1.2m, Q1 2025 1.2m, Q2 2025 1.2m
20 CAMP4 THERAPEUTICS CORP COM CAMP CAMP 2,927,915 $4.2m1.63% 1.63% UnchangedShares held: Q3 2024 0, Q4 2024 2.9m, Q1 2025 2.9m, Q2 2025 2.9m
21 ARTIVA BIOTHERAPEUTICS INC COM ARTV ARTV 2,353,304 $3.6m1.37% 1.37% UnchangedShares held: Q3 2024 2.4m, Q4 2024 2.4m, Q1 2025 2.4m, Q2 2025 2.4m
22 SURROZEN INC COM NEW SRZN SRZN 310,000 $2.8m1.07% 1.07% UnchangedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 310.0k, Q2 2025 310.0k
23 SILENCE THERAPEUTICS PLC ADS SLN SLN 476,200 $2.8m1.06% 1.06% UnchangedShares held: Q3 2024 476.2k, Q4 2024 476.2k, Q1 2025 476.2k, Q2 2025 476.2k
24 PROTARA THERAPEUTICS INC COM STK TARA TARA 800,000 $2.4m0.93% 0.93% UnchangedShares held: Q3 2024 0, Q4 2024 800.0k, Q1 2025 800.0k, Q2 2025 800.0k
25 ALECTOR INC COM ALEC ALEC 995,841 $1.4m0.54% 0.54% UnchangedShares held: Q3 2024 0, Q4 2024 995.8k, Q1 2025 995.8k, Q2 2025 995.8k
26 RALLYBIO CORP COM COM 3,630,724 $1.2m0.47% 0.47% UnchangedShares held: Q3 2024 3.6m, Q4 2024 3.6m, Q1 2025 3.6m, Q2 2025 3.6m
27 ADVERUM BIOTECHNOLOGIES INC COM NEW ADVM ADVM 541,666 $1.2m0.45% 0.45% UnchangedShares held: Q3 2024 541.7k, Q4 2024 541.7k, Q1 2025 541.7k, Q2 2025 541.7k
28 ZENTALIS PHARMACEUTICALS INC COM ZNTL ZNTL 490,000 $568.4k0.22% 0.22% UnchangedShares held: Q3 2024 490.0k, Q4 2024 490.0k, Q1 2025 490.0k, Q2 2025 490.0k
29 MERSANA THERAPEUTICS INC COM COM 1,305,000 $386.3k0.15% 0.15% UnchangedShares held: Q3 2024 1.3m, Q4 2024 1.3m, Q1 2025 1.3m, Q2 2025 1.3m

Sold out since Q1 2025

SecurityTickerShares held beforeValue then
ANAPTYSBIO INC ANAB ANAB 357,733 $6.7m357.7k shares
CIDARA THERAPEUTICS INC CDTX CDTX 56,725 $1.2m56.7k shares